APLT - Applied Therapeutics, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
New York,
United States
Type: Equity
APLT price evolution
APLT
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $122.2 | $146.48 | $49.9 | |
| Short term investments | ||||
| Net receivables | $0.26 | $0.26 | $0.26 | |
| Inventory | ||||
| Total current assets | $104.6 | $127.57 | $150.91 | $54.39 |
| Long term investments | ||||
| Property, plant & equipment | $1.96 | $0.21 | $0.33 | $0.45 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $0.21 | $0.33 | $0.45 | |
| Total investments | ||||
| Total assets | $106.57 | $127.78 | $151.23 | $54.83 |
| Current liabilities | ||||
| Accounts payable | $2.84 | $2.68 | $4.02 | $1.74 |
| Deferred revenue | ||||
| Short long term debt | $0.18 | $0.31 | $0.43 | |
| Total current liabilities | $98.97 | $55.36 | $83.91 | $71.18 |
| Long term debt | $0.03 | $0.04 | $0.04 | |
| Total noncurrent liabilities | $0.03 | $0.04 | $0.8 | |
| Total debt | $0.21 | $0.34 | $0.47 | |
| Total liabilities | $100.67 | $55.39 | $83.94 | $71.98 |
| Shareholders' equity | ||||
| Retained earnings | -$618.22 | -$549.63 | -$552.52 | -$468.59 |
| Other shareholder equity | ||||
| Total shareholder equity | $72.39 | $67.29 | -$17.15 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $49.9 | $16.66 | $53.89 | $57.47 |
| Short term investments | $13.92 | $26.93 | $39.36 | |
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $54.39 | $37.31 | $88.39 | $102.59 |
| Long term investments | ||||
| Property, plant & equipment | $0.45 | $0.86 | $1.3 | $1.71 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $0.45 | $1.05 | $1.5 | $1.91 |
| Total investments | $13.92 | $26.93 | $39.36 | |
| Total assets | $54.83 | $38.36 | $89.89 | $104.51 |
| Current liabilities | ||||
| Accounts payable | $1.74 | $4.53 | $9.46 | $0.64 |
| Deferred revenue | ||||
| Short long term debt | $0.43 | $0.48 | $0.44 | $0.41 |
| Total current liabilities | $71.18 | $33.42 | $26.46 | $21.23 |
| Long term debt | $0.04 | $0.41 | $0.89 | $1.33 |
| Total noncurrent liabilities | $0.8 | $0.88 | $0.89 | $1.33 |
| Total debt | $0.47 | $0.89 | $1.33 | $1.74 |
| Total liabilities | $71.98 | $34.3 | $27.35 | $22.57 |
| Shareholders' equity | ||||
| Retained earnings | -$468.59 | -$348.82 | -$266.31 | -$160.73 |
| Other shareholder equity | $0.05 | -$0.11 | -$0.11 | |
| Total shareholder equity | -$17.15 | $4.06 | $62.54 | $81.94 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $0.14 | $0.19 | -$0.67 | |
| Cost of revenue | ||||
| Gross Profit | $0.14 | $0.19 | -$0.67 | |
| Operating activities | ||||
| Research & development | $10 | $12.22 | $15.3 | |
| Selling, general & administrative | $10.58 | $9.07 | $5.04 | |
| Total operating expenses | $20.58 | $21.28 | $20.34 | |
| Operating income | -$20.44 | -$21.09 | -$21.01 | |
| Income from continuing operations | ||||
| EBIT | $2.9 | -$83.94 | -$37.68 | |
| Income tax expense | ||||
| Interest expense | ||||
| Net income | ||||
| Net income | $2.9 | -$83.94 | -$37.68 | |
| Income (for common shares) | $2.9 | -$83.94 | -$37.68 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $9.99 | |||
| Cost of revenue | ||||
| Gross Profit | $9.99 | |||
| Operating activities | ||||
| Research & development | $53.91 | $55.63 | $62.57 | $61.79 |
| Selling, general & administrative | $20.62 | $27.32 | $43.05 | $32.68 |
| Total operating expenses | $74.53 | $82.95 | $105.62 | $94.47 |
| Operating income | -$64.53 | -$82.95 | -$105.62 | -$94.47 |
| Income from continuing operations | ||||
| EBIT | -$119.76 | -$82.51 | -$105.03 | -$93.4 |
| Income tax expense | ||||
| Interest expense | $0.56 | $0.56 | ||
| Net income | ||||
| Net income | -$119.76 | -$82.51 | -$105.58 | -$93.96 |
| Income (for common shares) | -$119.76 | -$82.51 | -$105.58 | -$93.96 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | $2.9 | -$83.94 | -$37.68 | |
| Operating activities | ||||
| Depreciation | $0.12 | $0.12 | $0.01 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $1.89 | $2.38 | $1.63 | |
| Total cash flows from operations | -$22.59 | -$18.91 | -$17 | |
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | ||||
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | -$1.69 | $115.81 | $29.91 | |
| Net borrowings | -$0.31 | -$0.47 | ||
| Total cash flows from financing | $113.81 | -$1.69 | $115.5 | $29.45 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $48.97 | -$24.29 | $96.59 | $12.44 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$119.76 | -$82.51 | -$105.58 | -$93.96 |
| Operating activities | ||||
| Depreciation | $0.35 | $0.44 | $0.41 | $0.38 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $7.36 | $9.6 | $11.18 | $8.03 |
| Total cash flows from operations | -$55.17 | -$78.09 | -$90.73 | -$78.21 |
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | $13.87 | $13.17 | $12.43 | -$19.47 |
| Total cash flows from investing | $13.87 | $13.17 | $12.43 | -$19.47 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $64.6 | $27.86 | $74.93 | $135.92 |
| Net borrowings | -$0.31 | -$0.17 | -$0.28 | $1.07 |
| Total cash flows from financing | $74.54 | $27.69 | $74.72 | $136.29 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $33.24 | -$37.23 | -$3.58 | $38.62 |
News
Fundamentals
| Market cap | $73.07M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 116.36M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | -4.20 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 1.06 |
| Quick ratio | N/A |